San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Escient Pharmaceuticals is raising $120,000,000.00 in new funding. Sources indicate as part of senior management Chief Scientific Officer, Marcus Boehm played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Escient Pharmaceuticals
Escient Pharmaceuticals. We are a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications.

To learn more about Escient Pharmaceuticals, visit http://www.escientpharma.com/

Contact:
Marcus Boehm, Chief Scientific Officer
858-617-8220

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved